menu
    • menu
    [{"orgOrder":0,"company":"WCCT Global","sponsor":"ImmunoMolecular Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"D-Methyldopa","moa":"||Adrenergic-alpha-2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ WCCT Global"},{"orgOrder":0,"company":"WCCT Global","sponsor":"WCCT Global","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||PTH1R","graph1":"Undisclosed","graph2":"Phase I","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WCCT Global \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"WCCT Global \/ WCCT Global"}]

    Find Clinical Drug Pipeline Developments & Deals by WCCT Global

    Menu

    WCCT Global

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MT1013,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Shaanxi Micot Technology Limited Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MT1013 Clinical TRIAL In Healthy Subject

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 05, 2021

                            Lead Product(s) : MT1013,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Shaanxi Micot Technology Limited Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMT-002,D-Methyldopa

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : ImmunoMolecular Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 12, 2020

                            Lead Product(s) : IMT-002,D-Methyldopa

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : ImmunoMolecular Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Stanford University | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 27, 2019

                            Lead Product(s) : Live, Wild-Type A/california/H1 N1 2009 Influenza Virus,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Stanford University | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Norwalk GI.1 Virus,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Vaxart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 26, 2018

                            Lead Product(s) : Norwalk GI.1 Virus,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Vaxart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Recipient : Dance Biopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 11, 2017

                            Lead Product(s) : Insulin Lispro,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Recipient : Dance Biopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berdazimer Sodium,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Novan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 16, 2016

                            Lead Product(s) : Berdazimer Sodium,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Novan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PUL-042,Sodium Cromoglicate,Salbutamol Sulphate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Pulmotect

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 02, 2015

                            Lead Product(s) : PUL-042,Sodium Cromoglicate,Salbutamol Sulphate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Pulmotect

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NGP 555,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : NeuroGenetic Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 02, 2015

                            Lead Product(s) : NGP 555,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : NeuroGenetic Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            WCCT Global

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOD-4023,Inapplicable

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : OPKO Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 16, 2015

                            Lead Product(s) : MOD-4023,Inapplicable

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : OPKO Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth